TY  - JOUR
AU  - Matsushita, Kunihiro
AU  - Kaptoge, Stephen
AU  - Hageman, Steven Hj
AU  - Sang, Yingying
AU  - Ballew, Shoshana H
AU  - Grams, Morgan E
AU  - Surapaneni, Aditya
AU  - Sun, Luanluan
AU  - Arnlov, Johan
AU  - Bozic, Milica
AU  - Brenner, Hermann
AU  - Brunskill, Nigel J
AU  - Chang, Alex R
AU  - Chinnadurai, Rajkumar
AU  - Cirillo, Massimo
AU  - Correa, Adolfo
AU  - Ebert, Natalie
AU  - Eckardt, Kai Uwe
AU  - Gansevoort, Ron T
AU  - Gutierrez, Orlando
AU  - Hadaegh, Farzad
AU  - He, Jiang
AU  - Hwang, Shih Jen
AU  - Jafar, Tazeen H
AU  - Jassal, Simerjot K
AU  - Kayama, Takamasa
AU  - Kovesdy, Csaba P
AU  - Landman, Gijs W
AU  - Levey, Andrew S
AU  - Lloyd-Jones, Donald M
AU  - Major, Rupert W
AU  - Miura, Katsuyuki
AU  - Muntner, Paul
AU  - Nadkarni, Girish N
AU  - Nowak, Christoph
AU  - Ohkubo, Takayoshi
AU  - Pena, Michelle J
AU  - Polkinghorne, Kevan R
AU  - Sairenchi, Toshimi
AU  - Schaeffner, Elke
AU  - Schneider, Markus P
AU  - Shalev, Varda
AU  - Shlipak, Michael G
AU  - Solbu, Marit D
AU  - Stempniewicz, Nikita
AU  - Tollitt, James
AU  - Valdivielso, José M
AU  - van der Leeuw, Joep
AU  - Wang, Angela Yee Moon
AU  - Wen, Chi Pang
AU  - Woodward, Mark
AU  - Yamagishi, Kazumasa
AU  - Yatsuya, Hiroshi
AU  - Zhang, Luxia
AU  - Dorresteijn, Jannick An
AU  - Di Angelantonio, Emanuele
AU  - Visseren, Frank Lj
AU  - Pennells, Lisa
AU  - Coresh, Josef
TI  - Including Measures of Chronic Kidney Disease to Improve Cardiovascular Risk Prediction by SCORE2 and SCORE2-OP.
JO  - European journal of preventive cardiology
VL  - 30
IS  - 1
SN  - 2047-4873
CY  - London [u.a.]
PB  - Sage Publ.
M1  - DKFZ-2022-01878
SP  - 8-16
PY  - 2023
N1  - 2023 Jan 11;30(1):8-16
AB  - The 2021 ESC guideline on cardiovascular disease (CVD) prevention categorizes moderate and severe chronic kidney disease (CKD) as high and very-high CVD risk status regardless of other factors like age and does not include estimated glomerular filtration rate (eGFR) and albuminuria in its algorithms, SCORE2 and SCORE2-OP, to predict CVD risk. We developed and validated an 'Add-on' to incorporate CKD measures into these algorithms, using a validated approach.In 3,054,840 participants from 34 datasets, we developed three Add-ons (eGFR only, eGFR + urinary albumin-to-creatinine ratio [ACR] [the primary Add-on], and eGFR + dipstick proteinuria) for SCORE2 and SCORE2-OP. We validated c-statistics and net reclassification improvement (NRI), accounting for competing risk of non-CVD death, in 5,997,719 participants from 34 different datasets.In the target population of SCORE2 and SCORE2-OP without diabetes, the CKD Add-on (eGFR only) and CKD Add-on (eGFR + ACR) improved c-statistic by 0.006 (95
KW  - cardiovascular disease (Other)
KW  - chronic kidney disease (Other)
KW  - meta-analysis (Other)
KW  - risk prediction (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:35972749
DO  - DOI:10.1093/eurjpc/zwac176
UR  - https://inrepo02.dkfz.de/record/181232
ER  -